Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 4 (2007), Issue 8 (August)

  1. The surgical learning curve for prostate cancer control after radical prostatectomy.
    J Natl Cancer Inst, 99(15): 1171-7. [Abstract] [Full-text]
  2. Prospective study of fruit and vegetable intake and risk of prostate cancer.
    J Natl Cancer Inst, 99(15): 1200-9. [Abstract] [Full-text]
  3. Cylindroma of the prostate.
    Am J Surg Pathol, 31(8): 1288-91. [Abstract] [Full-text]
  4. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Am J Surg Pathol, 31(8): 1246-55. [Abstract] [Full-text]
  5. Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma.
    Am J Surg Pathol, 31(8): 1225-30. [Abstract] [Full-text]
  6. Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells.
    Biochem Biophys Res Commun, 361(1): 169-75. [Abstract] [Full-text]
  7. Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells.
    Biochem Biophys Res Commun, 361(1): 189-95. [Abstract] [Full-text]
  8. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Nature, 448(7153): 595-9. [Abstract] [Full-text]
  9. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.
    Cancer Res, 67(15): 7525-33. [Abstract] [Full-text]
  10. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.
    Cancer Res, 67(15): 7458-66. [Abstract] [Full-text]
  11. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
    Cancer Res, 67(15): 7450-7. [Abstract] [Full-text]
  12. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.
    Cancer Res, 67(15): 7439-49. [Abstract] [Full-text]
  13. An algorithm for managing the failure of external beam radiotherapy in prostate cancer.
    BJU Int, 100(3): 518-27. [Abstract] [Full-text]
  14. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin.
    BJU Int, 100(3): 528-32. [Abstract] [Full-text]
  15. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
    BJU Int, 100(3): 533-5. [Abstract] [Full-text]
  16. Does active surveillance for men with localized prostate cancer carry psychological morbidity?
    BJU Int, 100(3): 540-3. [Abstract] [Full-text]
  17. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
    BJU Int, 100(3): 514-7. [Abstract] [Full-text]
  18. Bad expression influences time to androgen escape in prostate cancer.
    BJU Int, 100(3): 691-6. [Abstract] [Full-text]
  19. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men.
    BJU Int, 100(3): 685-90. [Abstract] [Full-text]
  20. A randomized controlled trial of topical glyceryl trinitrate before transrectal ultrasonography-guided biopsy of the prostate.
    BJU Int, 100(3): 536-8; discussion 538-9. [Abstract] [Full-text]
  21. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance.
    BJU Int, 100(3): 544-51. [Abstract] [Full-text]
  22. Radical prostatectomy for clinical T3 disease: expanding indications while optimizing cancer control and quality of life.
    Nat Clin Pract Urol, 4(8): 451-4. [Abstract] [Full-text]
  23. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
    J Nucl Med, 48(8): 1327-37. [Abstract] [Full-text]
  24. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.
    Mol Cell, 27(3): 380-92. [Abstract] [Full-text]
  25. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
    Invest New Drugs, 25(5): 445-51. [Abstract] [Full-text]
  26. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.
    Cancer, 110(4): 906-10. [Abstract] [Full-text]
  27. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
    BMC Cancer, 7: 142. [Abstract] [Full-text]
  28. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy.
    J Gen Intern Med, 22(9): 1305-10. [Abstract] [Full-text]
  29. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
    J Urol, 178(3): 1086-91. [Abstract] [Full-text]
  30. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy.
    J Urol, 178(3): 990-5. [Abstract] [Full-text]
  31. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.
    J Urol, 178(3): 826-31; discussion 831-2. [Abstract] [Full-text]
  32. Predictors of histological disease progression in untreated, localized prostate cancer.
    J Urol, 178(3): 833-7. [Abstract] [Full-text]
  33. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    J Urol, 178(3): 860-3; discussion 863. [Abstract] [Full-text]
  34. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    J Urol, 178(3): 864-70; discussion 870-1. [Abstract] [Full-text]
  35. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.
    J Urol, 178(3): 844-8; discussion 848. [Abstract] [Full-text]
  36. Prospective evaluation of short-term impact and recovery of health related quality of life in men undergoing robotic assisted laparoscopic radical prostatectomy versus open radical prostatectomy.
    J Urol, 178(3): 854-8; discussion 859. [Abstract] [Full-text]
  37. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
    J Urol, 178(3): 849-53; discussion 853; quiz 1129. [Abstract] [Full-text]
  38. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.
    J Urol, 178(3): 838-43; quiz 1129. [Abstract] [Full-text]
  39. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions.
    Endocrinology, 148(9): 4334-43. [Abstract] [Full-text]
  40. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
    J Clin Oncol, 25(24): 3603-8. [Abstract] [Full-text]
  41. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
    J Clin Oncol, 25(24): 3596-602. [Abstract] [Full-text]
  42. Assessing individual risk for prostate cancer.
    J Clin Oncol, 25(24): 3582-8. [Abstract] [Full-text]
  43. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer.
    J Clin Oncol, 25(24): 3576-81. [Abstract] [Full-text]
  44. Monte Carlo calculation of rectal dose when using an intrarectal balloon during prostate radiation therapy.
    Med Dosim, 32(3): 151-6. [Abstract] [Full-text]
  45. Steroid receptor RNA activator (SRA1): unusual bifaceted gene products with suspected relevance to breast cancer.
    Nucl Recept Signal, 5: e006. [Abstract] [Full-text]
  46. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.
    Oncology, 71(3): 168-75. [Abstract] [Full-text]
  47. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Am J Surg Pathol, 31(9): 1351-5. [Abstract] [Full-text]
  48. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
    Am J Surg Pathol, 31(9): 1323-9. [Abstract] [Full-text]
  49. The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells.
    Cancer Lett, 255(2): 300-6. [Abstract] [Full-text]
  50. TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer.
    Cancer Immunol Immunother, 56(11): 1785-93. [Abstract] [Full-text]
  51. Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells.
    Biochem Biophys Res Commun, 362(1): 212-7. [Abstract] [Full-text]
  52. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
    Nat Clin Pract Oncol, 4(9): 551-4. [Abstract] [Full-text]
  53. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
    J Clin Oncol, 25(25): 3965-70. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

Conquer Prostate Cancer: How Medicine, Faith, Love and Sex Can Renew Your Life

Conquer Prostate Cancer: How Medicine, Faith, Love and Sex Can Renew Your Life